Skip to main content

Test Price

950 AED

✅ Home Collection Available

PD-1 Immunohistochemistry (IHC) Test in UAE | 950 AED | DHA-Regulated Cancer Biomarker Analysis

Executive Summary & Core Metrics

Core Performance Indicators

  • Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
  • Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval for archival FFPE blocks and biopsy slides; temperature-controlled chain of custody maintained throughout transport.
  • Clinical Guidance: Complimentary telephonic post-test consultation with our oncology support team to interpret results.
  • Insurance: Direct Billing Verification available via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This advanced immunohistochemistry test detects PD-1 protein expression on tumor-infiltrating lymphocytes and tumor cells, guiding immunotherapy decisions in lung cancer, melanoma, colon cancer, and other solid malignancies. The assay employs automated IHC platforms with validated monoclonal antibodies (clone NAT105) and digital image analysis, delivering reliable results within 5–7 working days under strict ISO 9001:2015 quality controls.

Feature Our DHA-Regulated PD-1 IHC Alternative (Generic IHC / Genetic Panel)
Methodology Automated IHC with digital image analysis (PD-1 clone NAT105) Manual IHC or RT-PCR gene expression, often less standardized
Turnaround Time 5 days (FFPE block) / 7 days (complex resection) 7–14 days, variable
Accreditation ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139), DHA-licensed Facility 1143 Often lacking local UAE accreditation
Clinical Support Telephonic post-test interpretation by oncology support team Limited or no integrated guidance

Physician Insight & Safety Protocols

“PD-1 immunohistochemistry results must be correlated with full histopathological assessment and the patient’s complete clinical history to minimize the risk of false negatives. This biomarker assay is a powerful component of precision oncology but should always be integrated into a multidisciplinary treatment plan. Patients are advised to discuss all results with their treating physician before initiating or modifying any therapeutic regimen.” — Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011

Exclusion Criteria & Critical Safety Notice

  • Inadequate or necrotic tissue sample may yield inconclusive results.
  • Decalcified or improperly fixed tissue compromises antigen integrity and is unsuitable for analysis.
  • Specimens from patients under 18 years are processed only with explicit guardian consent and specialist oncology approval per UAE pediatric guidelines.

If you experience unexpected symptoms such as high fever, active bleeding at the biopsy site, or escalating pain, seek emergency medical attention without delay.

Patient FAQ & Clinical Guidance

1. What is the purpose of the PD-1 immunohistochemistry test?

This test precisely measures PD-1 protein levels in tumor tissue to help predict patient response to immune checkpoint inhibitor therapies such as pembrolizumab and nivolumab. The results guide oncologists in personalizing cancer treatment plans and monitoring immunotherapy efficacy over time.

2. How should I prepare for sample submission?

No specific patient preparation is needed. The tissue sample must be submitted as a formalin-fixed paraffin-embedded (FFPE) block or as biopsy slides accompanied by the full histopathology report and clinical history. Our courier service retrieves the specimen directly from the treating hospital or clinic, maintaining a strict temperature-controlled chain of custody.

3. When will I receive my PD-1 IHC results?

Results are typically reported within 5 working days for standard FFPE blocks and up to 7 working days for large or complex surgical resections. A complimentary telephonic consultation with our oncology support team is provided to help you and your physician interpret the findings and determine next steps.

4. Can the test be performed on a blood sample?

No. PD-1 immunohistochemistry requires solid tumor tissue, specifically an FFPE block or histological slides. Blood-based assays cannot substitute for this tissue-dependent analysis. Our secure courier service handles all archival tissue specimen logistics from the referring medical facility.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance Framework

This diagnostic service operates in full compliance with UAE healthcare data protection and medical liability regulations. All patient data is secured under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.

DNA Labs UAE is a DHA-licensed facility (License Number 1143) operating from Dubai Healthcare City. All immunohistochemistry testing is performed under ISO 9001:2015 certified quality management systems.

Clinical & Logistical Metadata

Test Name PD-1 Immunohistochemistry (IHC)
Price (AED) 950 AED
Turnaround Time 5 to 7 working days
Sample Type / Matrix Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block or Biopsy Slides
Methodology Used Automated Immunohistochemistry (IHC) with validated monoclonal antibodies (clone NAT105) and digital image analysis
ICD-10-CM Code Z85.9
LOINC Code 94691-7
DHA Facility License & Laboratory Address DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians